Drug intelligence / Profile preview

Acumol

Development stage: Unknown
Lead developer: Acure Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Acumol** is an oral analgesic and antipyretic product series associated with Acure Pharma. Publicly available pipeline context identifies Acumol formulations containing paracetamol and aceclofenac; therefore, the name does not unambiguously identify one fixed composition. Paracetamol provides centrally mediated analgesic and antipyretic effects through an incompletely defined mechanism that may involve reduced prostaglandin synthesis, while aceclofenac is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-mediated prostaglandin production to reduce pain and inflammation.

Brand names: Acumol

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Acumol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acumol.

Explore the full profile